

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313/1450 on

February 20, 2004

Date

Serial No:

10/681,431

Filed:

October 8, 2003

Applicant:

Moore

Title:

N-Desmethyl Levomepromazine

Art Unit:

1714

Conf. No.:

7143

Examiner:

Unknown

Atty Dkt:

**XANO-33** 

Cincinnati, Ohio 45202

February 20, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## **INFORMATION DISCLOSURE STATEMENT**

In accordance with the duty of candor and good faith which is imposed by Rule 56 (37 C.F.R. §1.56), the art listed on the attached form PTO-1449 is called to the attention of the U.S. Patent and Trademark Office in connection with the above identified patent application. Copies of the cited references are provided. No representation is made that the cited art is the only art or that the cited art represents the best art.

The Examiner is urged to consider the cited references and to make an independent decision with respect to their materiality.

Applicant does not believe there is any fee due with this submission.

Should any fees or surcharges be deemed necessary, Examiner has authorization to charge fees or credit any overpayment to Deposit Account No. 23-3000. The Examiner is invited to telephone the undersigned attorney if there are any questions or issues.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

Beeeely A Lyman
Beverly A. Lyman

Reg. No. 41,961

2700 Carew Tower Cincinnati OH 45202 (513) 241-2324 (513) 421-7269 facsimile

SUBSTITUTE (MODIFIED)	FORM F	PTO-14	449	)		U	S. DEPARTME	NT OF COMME	RCE FICE	ATTY. XANO	DOCKET N 33	O.	SERIAL NO. 10/681,431		
		-				DISC	OSURE PLICANT	4		APPLIC Keith N					
(37 CFR 1.98(	b))	(L	Jse	sever	al she	ets if n	ecessary)	FEB 2 4 2004	5.		DATE er 8, 2003		GROL 1714	JP	
(0.01.11.11.11.11.11.11.11.11.11.11.11.11							U.S. P	TENT:DOOM	ENTS	<u> </u>				<del>-</del>	
EXAMINER INITIAL		F	PAT	ENT	NUME	ER	ISSUE DATE	PATEN	TEE		CLASS	SUBC	LASS	FILING DATE IF APPROPRIATE	
	A.A														
	A.B														
	A.C													<u> </u>	
	A.D														
	A.E														
	A.F											1			
	A.G											<u> </u>			
	A.H									_		ļ			
	A.I									···· <u>-</u>					
	A.J									· <del></del>					
	A.K														
				F	OREI	GN PA	TENTS OR PUB	LISHED FOREI	GN PA	ATENT A	PPLICATIO	NS			
		DOCUMENT NUMBER					PUBLICATION DATE		COUNTRY OR PATENT OFFICE			SUBCLASS		TRANSLATION (YES/NO)	
	A.L	06121698				06	6-05-94	Japan			C12Q	1/68		Abstract only	
	A.M						-	<u>.</u>							
	A.N														
	A.O														
	A.P														
	A.Q							<u></u> .							
					OTHE	R DOC	CUMENTS (Inclu	ding Author, Title	e, Date	e, Place	of Publicatio	n)			
	A.R					rmaco ; 19:43	kinetics of metho 5-442	otrimeprazine af	ter sin	gle and r	nultiple dose	es, Clinical	Pharm	acology and	
	A.S Dahl, Svein, G., Active Metabolites of Neuroleptic Drugs: Possible Contribution to Therapeutic and Toxic Effects, Therapeutic Drug Monitoring, 1982; 1:33-40										c Effects,				
	A.T	Dahi Psyd	I, S chia	vein ( itric P	3, et a atient	I., <u>Plas</u> s, Ther	ma and Erythroc apeutic Drug Mo	yte Levels of Menitoring, 1982; 4	thotrir :81-87	meprazin '	e and Two o	of Its Nonp	olar Me	tabolites in	
EXAMINER									DATE CONSIDERED						
EXAMINER: I	nitial if c	itation	COI	nsider	ed, w	nether o	or not in conform	ance. Draw line	throu	gh citatio	on only if not	in conform	nance <u>a</u>	nd not considered.	

Sheet 2 (B) of 3

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF PATENT AND TRADEM															SERIAL NO. 10/681,431		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT											APPLIC Keith M						
(37 CFR 1.98	ı	(Use	seve	eral s	sheet	s if ne	ecessary)			FILING Octobe	DATE er 8, 2003		GROU 1714	Р			
			U.S. PATENT DOCUMENTS														
EXAMINER INITIAL			PA	TENT	NUI	MBER	R ISSUE DATE			PATENTEE	CLASS		SUBC	LASS	FILING DATE IF APPROPRIATE		
	B.A																
	B.B																
	B.C																
	B.D																
	B.E																
	B.F																
	B.G														<u> </u>		
	в.н									<del></del>							
	B.I										. <u>.</u>						
	B.J								<u></u>								
	в.к								<u> </u>		·		<u> </u>				
					FOR	EIGN	PAT	ENTS OR PL	BLISHED	FOREIGN PA	TENT A	PPLICATION	IS				
		DOCUMENT NUMBER					Р	UBLICATION DATE		COUNTRY OF			SUBCLASS		TRANSLATION (YES/NO)		
	B.L																
	В.М						ļ			<u></u>							
	B.N																
	B.O																
	B.P				_												
	B.Q					_		<u>.</u>					•				
					ОТІ	HER	DOC	UMENTS (Inc	luding Au	thor, Title, Date	e, Place o	of Publication	1)				
	B.R	Gennaro, Alfonso R, Ed., <u>Chapter 45 Oral Solid Dosage Forms</u> , Remington: The Science and Practice of Pharmacy, 200 Edition, 2000, Mack Publishing Co., PA, pp.878-893											of Pharmacy, 20th				
	B.S	Gibson, Ed., Pharmaceutical Preformulation and Formulation, IHS Health Group, Englewood CO, 2001 pp. 331-354, 379-458  Hals, PA et al., Metabolism of levomepromazine in man, European Journal of Drug Metabolism and Pharmacokinetics, 1995; 20:61-71											pp. 331-354, 379-				
	в.т												rmacokinetics,				
EXAMINER	AMINER									DATE CONSIDERED							
EXAMINER: I	Initial if ci	tatio	n co	nside next	red,	whet	her o	r not in confor n to applicant	mance. [	Draw line throu	gh citatio	n only if not i	n conforn	nance <u>ar</u>	nd not considered.		

Sheet 3 (C) of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)								U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE					ATTY. DOCKET NO. XANO/33				SERIAL NO. 10/681,431		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT														APF Keit		ANT oore			
(07 OFD 4 00)	/L\\		(Use	e se	vera	ıl she	eets	if ne	cessa	y)			FILING DATE					GROUP	
(37 CFR 1.98)	D))												October 8, 2003 1714						
	1	Т					_	- 1			AIEN	11 000	CUMENTS				T		EN INC DATE
EXAMINER INITIAL	ļ		PA.	TEN	IT N	UME	BER	R DATE				PA	ATENTEE			CLASS	SUBCLASS		FILING DATE IF APPROPRIATE
	C.A																		
	С.В												_						
	c.c														<u>.</u>				
	C.D																		
	C.E									_									
	C.F																		
	C.G																		
-:-	C.H					П													
	C.I																		
	C.J												···			·			
	с.к	T		T		П													
	•			•	FC	REI	GN	PAT	ENTS	OR PU	BLISH	ED FO	REIGN PA	ATENT	ГΑР	PLICATION	18	•	
		DOCUMENT NUMBER											COUNTRY OR PATENT OFFICE			CLASS	SUBCLASS		TRANSLATION (YES/NO)
	C.L																		
	C.M																		
	C.N																		
	C.O													_					
/***	C.P														$\top$				
	C.Q				-	-	$\neg$								$\top$				
					0	THE	RC	OCL	JMENT	rs (Incl	uding	Author	, Title, Dat	e, Plac	ce of	Publication	1)		
_	C.R	Sztrubar Let al. Liquid chromatographic resolution										ition of	on of the enantiomers of psychotropic drug levomepromazine d chiral stationary phase, Journal of Pharmaceutical & Biomedical						
	C.S										_		· · · · ·						
	C.T																		
EXAMINER											D.	DATE CONSIDERED							
EXAMINER:	nitial if ci	tatio	n co	nsio	dere	d, w	heth	er o	r not in	confor	mance	e. Drav	w line throu	gh cita	ation	only if not i	in conform	nance <u>a</u>	nd not considered.